Premium
Biologics in oral medicine: principles of use and practical considerations
Author(s) -
O’Neill ID,
Scully C
Publication year - 2012
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.2012.01919.x
Subject(s) - medicine , oral medicine , intensive care medicine , rheumatoid arthritis , psoriasis , infliximab , inflammatory bowel disease , ankylosing spondylitis , adverse effect , disease , alternative medicine , dermatology , immunology , pathology , dentistry
Oral Diseases (2012) 18, 525–536 Biologic therapies are relatively innovative treatments aimed at modulating lymphocytes or cytokines. There are currently three broad classes of biologic therapies, tumour necrosis factor‐alpha inhibitors, lymphocyte modulators and interleukin inhibitors; all are increasingly used in the treatment of inflammatory immune‐mediated conditions, and several have potential applications in oral medicine. Guidelines for their use in licensed indications (e.g. rheumatoid arthritis, psoriasis, inflammatory bowel disease) include recommendations and guidance for patient selection and subsequent monitoring with discussion of potential adverse effects. An understanding of these is important when managing patients receiving biologic therapy for systemic disease, and compliance is essential in any use in oral medicine. Key aspects of current guidance are presented with particular emphasis on their relevance to clinicians working within oral and maxillofacial medicine/pathology/surgery and in specialist practice.